Analysis of preoperative risk factors for early recurrence after curative pancreatoduodenectomy for resectable pancreatic adenocarcinoma
Author:
Burasakarn Pipit1ORCID, Thienhiran Anuparp1, Fuengfoo Pusit1, Hongjinda Sermsak1
Affiliation:
1. Division of HPB Surgery, Department of Surgery , Phramongkutklao Hospital , Bangkok , Thailand
Abstract
Abstract
Objectives
To investigate the risk factors for early recurrence after curative pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
Methods
All data were retrospectively collected from patients with resectable pancreatic ductal adenocarcinoma who had undergone pancreatoduodenectomy at the Department of Surgery, Phramongkutklao Hospital, from January 2015 to December 2020. The preoperative and perioperative risk factors were included into the analysis.
Results
In total, 34 patients were included in the study. The median time for recurrence and median survival time were 17 and 20 months, respectively. The 1, 3, and 5 year disease-free survival rates were 59.6%, 23.87%, and 23.87%, respectively, while the 1, 3, and 5 year overall survival rates were 81%, 24.7%, and 12.4%, respectively. Seventeen patients (50%) from a total of 34 patients had recurrence, and ten patients (29.41%) had recurrence within 12 months. The independent preoperative risk factor associated with adverse disease-free survival was tumor size > 4 cm (hazard ratio [HR], 14.34, p=0.022). The perioperative risk factors associated with adverse disease-free survival were pathological lymphovascular invasion (HR, 4.31; p=0.048) and non-hepatopancreatobiliary surgeon (HR, 5.9; p=0.022). Risk factors associated with poor overall survival were microscopical margin positive (R1) resection (HR, 3.68; p=0.019) and non-hepatopancreatobiliary surgeon (HR, 3.45; p=0.031).
Conclusions
Tumor size > 4 cm from the preoperative imaging study was a poor prognostic factor for early recurrence after curative pancreatoduodenectomy for resectable pancreatic adenocarcinoma indicated that they may have radiological occult metastasis, thus, staging laparoscopy may reduce the number of unnecessary laparotomies and avoid missing radiologically negative metastases.
Publisher
Walter de Gruyter GmbH
Reference32 articles.
1. Jemal, A, Ward, EM, Johnson, CJ, Cronin, KA, Ma, J, Ryerson, B, et al.. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst 2017;109. 2. Jones, RP, Psarelli, EE, Jackson, R, Ghaneh, P, Halloran, CM, Palmer, DH, et al.. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg 2019;154:1038–48. 3. Zhang, Y, Frampton, AE, Kyriakides, C, Bong, JJ, Habib, N, Ahmad, R, et al.. Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. J Cancer Res Clin Oncol 2012;138:1063–71. 4. Oba, A, Ho, F, Bao, QR, Al-Musawi, MH, Schulick, RD, Del Chiaro, M. Neoadjuvant treatment in pancreatic cancer. Front Oncol 2020;10:245. 5. Liu, X, Fu, Y, Chen, Q, Wu, J, Gao, W, Jiang, K, et al.. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer. BMC Gastroenterol 2019;18:168.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|